Shots:
- Sanofi has reported the P-IIa (HS-OBTAIN) trial data assessing brivekimig (150mg, SC, Q2W) vs PBO in pts with mod. to sev. hidradenitis suppurativa, incl. biologic-naïve pts for 16 wks., followed by a 12wk. open-label period & an 8wk. safety follow-up
- At 16wks., brivekimig achieved higher HiSCR50 median response rates of 67% vs 37%, with 54% vs 22% pts achieving HiSCR75 & 31% vs 9% reaching HiSCR90; mean draining tunnel count change was -56.0% vs +10.9%; data was presented at EADV’25
- Brivekimig is a dual-target Nanobody that inhibits TNF and OX40-ligand & is being studied for multiple immune-mediated & inflammatory diseases
Ref: Sanofi | Image: Sanofi | Press Release
Related News:- Sanofi’s Tzield Receives the NMPA’s Approval to Delay Progression of Type 1 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
